Robertj Mentz News Today

Filling an evidence gap, a pooled analysis of patients with heart failure across the LVEF spectrum supports starting sacubitril-valsartan in the hospital.

Study did not meet primary endpoint for composite of death, heart failure hospitalization, and exercise function.

The largest ever study of IV iron supplementation in patients with heart failure failed to meet a new rigorous definition of significance, and the results were generally regarded as disappointing.

Robert J. Mentz, MD, and Javed Butler, MD, MPH, MBA, comment on the use of beta blockers and other agents in patients with heart failure preserved ejection fraction (HFpEF).

Robert J. Mentz, MD, reviews the current unmet needs for patients with heart failure, highlighting triple or quadruple therapy.

Drs James Januzzi, Javed Butler, Robert J. Mentz, and Muthiah Vaduganathan share approaches to sequencing quadruple therapy in heart failure to the individual patient, as well as optimizing therapy early in the hospitalization stage.

Robert J. Mentz, MD, and James Januzzi, MD, discuss the key takeaways from updated heart failure guidelines, highlighting heart failure stages A and B.

Randomized trial suggests benefit is largely in those with 40-60% ejection fraction

Javed Butler, MD, MPH, MBA, and Robert J. Mentz, MD, review the current prevalence of heart failure in the US and Europe, as well as the clinical and economic challenges that arise with increasing prevalence.

Two drugs widely used to treat adults with heart failure – furosemide and torsemide – showed no difference in their ability to improve patient survival when compared, according to findings from a clinical trial supported by the National Institutes of Health. The trial, one of the largest to date studying routine medications in heart failure,Two drugs widely used to treat adults with heart failure – furosemide and torsemide – showed no difference in their ability to improve patient surviv...